AzurRX Biopharma, which is developing non-systemic biologics for gastrointestinal disorders, announced terms for its IPO on Friday.
The Brooklyn, NY-based company plans to raise $15 million by offering 2.1 million shares at a price range of $6 to $8. At the midpoint of the proposed range, AzurRX Biopharma would command a fully diluted market value of $77 million.
AzurRX Biopharma was founded in 2007 and plans to list on the Nasdaq under the symbol AZRX. WallachBeth Capital and Network 1 Financial Securities are the joint bookrunners on the deal. No pricing date has been determined.
The article Gastro biotech AzurRX Biopharma sets terms for $15 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
